ClinicalTrials.gg

Program

isomyosamine

Its studies are mostly in Frailty, led by TNF Pharmaceuticals.

Furthest: phase 2, since Apr 9, 20251 company-led study, 1 open or running

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
TNF Pharmaceuticals11 open or runningphase 2since Apr 9, 2025Apr 9, 2025none ahead

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Apr 9, 2025First study: phase 2 study in FrailtyFirst studyNCT06942182 · 60 planned

TargetBeta

IL6 →read by rule
“Isomyosamine is a promising oral medication that reduces inflammation by targeting cytokines like TNF-α and IL-6, which are linked to these conditions.”study text, by rule · the study

Other programs on IL6

ProgramCompanyFurthest phaseStudies
olokizumabruleR-Pharmphase 319
ziltivekimabruleNovo Nordiskphase 312
clazakizumabCSLphase 310
pacibekitugruleNovartisphase 31

Studies

All 1 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT06942182Frailty2Not yet recruitingMar 1, 202660

How it is read

Names in the registry

  • “Isomyosamine 250mg”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.